MK-677 vs sermorelin: oral secretagogue or injectable GHRH analog?

MK-677 and sermorelin are the two most-asked-about ways to raise growth hormone without injecting GH itself. They aim at the same axis but enter it through different doors, and the practical differences — oral vs injected, approved vs not, and their safety profiles — are what should actually decide between them. For each on its own, see the MK-677 monograph and the sermorelin monograph.

Same axis, two entry points

Both are growth hormone secretagogues — they prompt your own pituitary to release more GH rather than supplying GH from outside. But they push different levers. MK-677 is an oral ghrelin mimetic: it acts on the ghrelin pathway to amplify pulsatile GH release and sustain elevated IGF-1.^[1] Sermorelin is a GHRH(1-29) analog — the active fragment of growth-hormone-releasing hormone — that stimulates the pituitary’s GHRH receptor, producing a more physiologic GH pulse.^[3] Same destination, different on-ramp.

Oral vs injectable, long vs short

The most obvious practical difference is convenience. MK-677 is a once-daily pill; sermorelin is a subcutaneous injection, typically at night. But the route ties to a deeper difference in how each shapes GH. MK-677’s long action keeps IGF-1 elevated continuously, which is potent but less like the body’s natural rhythm; sermorelin’s shorter action produces a GH pulse closer to physiologic — one reason it’s often framed as the “gentler” option. Whether continuous elevation or pulsatile mimicry is better for any given goal is, honestly, not settled by outcome trials for either drug.

The approval difference

This is the cleanest distinction. Sermorelin is a real, approved drug with a genuine clinical pedigree — it was FDA-approved (as Geref) for diagnosing and treating growth-hormone deficiency in children, though the brand was later discontinued for commercial reasons and it’s now supplied largely through compounding pharmacies.^[3] MK-677 was never approved for anything; despite a deep trial record, it remained investigational and is sold only as a research chemical. So sermorelin at least has a regulated history and a manufactured precedent; MK-677 does not.

The safety difference

What neither has proven

The honest equalizer: neither drug has shown the anti-aging, strength, or longevity outcomes they’re marketed for. MK-677 raised IGF-1 and lean mass without improving strength or function, and failed in Alzheimer’s and hip-fracture outcome trials.^[1] Sermorelin’s evidence for healthy-adult benefit is similarly built more on biomarkers than on hard outcomes. Both reliably move the GH-IGF-1 axis; neither has shown that doing so makes a healthy adult measurably better off.

The honest bottom line

If you frame it as a choice: sermorelin is the more conservative pick — an actual approved GHRH analog with a more physiologic action and fewer documented safety flags, now mostly compounded. MK-677 is more convenient (oral, once daily) and a more potent, sustained IGF-1 raiser — but it was never approved and carries the clearer metabolic and cardiac risks.^[2][3] Crucially, there is no head-to-head trial and no proven outcome benefit for either in healthy adults, so this is a comparison of profiles, not of demonstrated results. For the deeper dives, see the MK-677 side effects and sermorelin evidence pages.